Tregalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD4 |
| Clinical data | |
| Other names | BT-061 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, Jonuleit H, Kubach J, Dingermann T, Radeke HH, Osterroth F, Uherek C, Czeloth N, Schüttrumpf J (April 2015). "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway". Immunol Cell Biol. 93 (4): 396–405. doi:10.1038/icb.2014.102. PMC 4407014.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J (Jan 2016). "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells". Frontiers in Immunology. 7. doi:10.3389/fimmu.2016.00011. PMC 4724712.
{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |